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were higher in males than females by 14 and 18 %, respec-
tively. CL decreased with increasing albumin and decreas-
ing alkaline phosphatase. The final model was externally 
validated using 1670 concentrations from 146 Japanese 
patients that were not used for model-building. Mean pre-
diction errors were −2.1, 3.1 and 1.0 % for concentrations, 
CL and V1, respectively, confirming adequate predictive 
performance.
Conclusions A robust bevacizumab pharmacokinetic 
model was developed and externally validated, which may 
be used to simulate bevacizumab exposure to optimize dos-
ing strategies. Asian and non-Asian patients exhibited simi-
lar bevacizumab pharmacokinetics. Given the similarity in 
pharmacokinetics among monoclonal antibodies, this may 
inform pharmacokinetic studies in different ethnic groups 
for other therapeutic antibodies.
Keywords Population pharmacokinetics · Bevacizumab · 
Cancer · External validation · Japan · Adult · Asian
Introduction
Bevacizumab (Avastin®, Genentech Inc.) is a humanized 
monoclonal immunoglobulin G (IgG) 1 antibody that spe-
cifically binds and neutralizes the biological activity of vas-
cular endothelial growth factor A (VEGF-A), a key isoform 
of VEGF involved in angiogenesis, and a well-character-
ized pro-angiogenic factor [1]. Bevacizumab causes inhi-
bition of tumor angiogenesis by blocking VEGF-A from 
binding to its receptors and leads to tumor growth inhibi-
tion. Bevacizumab in combination with standard therapy 
has received marketing authorization for use in the treat-
ment of various cancers including metastatic colorectal 
cancer (CRC) [2, 3], non-small cell lung cancer (NSCLC) 
Abstract 
Background Bevacizumab is approved for various cancers. 
This analysis aimed to comprehensively evaluate bevaci-
zumab pharmacokinetics and the influence of patient vari-
ables on bevacizumab pharmacokinetics.
Methods Rich and sparse bevacizumab serum concentra-
tions were collected from Phase I through IV studies in 
early and metastatic cancers. Bevacizumab was given intra-
venously as single agent or in combination with chemo-
therapy for single- and multiple-dose schedules.
Results Model-building used 8943 bevacizumab concen-
trations from 1792 patients with colon/colorectal, non-
small cell lung, kidney, pancreatic, breast, prostate and 
brain cancer. Bevacizumab doses ranged from 1 to 20 mg/
kg given once every 1, 2 or 3 weeks. A two-compartment 
model best described the data. The population estimates 
of clearance (CL), central volume of distribution (V1) and 
half-life for a typical 70-kg patient were 9.01 mL/h, 2.88 L 
and 19.6 days. CL and V1 increased with body weight and 
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[4], breast cancer [5], renal cell carcinoma [6], cervical 
cancer [7] and ovarian cancer [8].
A population pharmacokinetic (PK) model has been pre-
viously developed [9]. Bevacizumab PK showed dose line-
arity within the dose range of 1–20 mg/kg, a slow clearance, 
a volume of distribution consistent with limited extravas-
cular distribution and a terminal half-life of approximately 
20 days. Clearance (CL) and central volume of distribution 
(V1) increased with body weight and were higher in male 
patients. CL decreased with increasing albumin and decreas-
ing alkaline phosphatase. There has been no evidence for 
anti-therapeutic antibodies (ATAs) for bevacizumab in met-
astatic solid tumors based on the large number of historical 
clinical studies, and ATA was detected in only 0.6 % of the 
patients with colon cancer (adjuvant setting) [10].
However, the previous analysis had several limitations. 
Several important covariates were not evaluated in previ-
ous analysis including ethnicity (e.g., Asian vs. non-Asian), 
indications and baseline VEGF-A. First, bevacizumab has 
been widely used across ethnic groups (e.g., Asian vs. non-
Asian), and supplementary Biologics License Applications 
have been submitted to health authorities for approval of 
using bevacizumab for new indications or new combina-
tions based on data from limited ethnic groups while the 
target population contains much broader ethnic groups. 
Therefore, it is important to evaluate ethnicity (Asian vs. 
non-Asian) as a covariate. Second, it has been shown that 
bevacizumab clearance is 50 % higher and exposure is 
50 % lower in gastric cancer as compared to other types 
of solid tumors [11], making it important to evaluate indi-
cation as a covariate. Finally, several studies have shown 
the predictive value of baseline VEGF-A for bevacizumab 
treatment effect on progression-free survival and/or over-
all survival, meaning that only patients with high VEGF-A 
levels may benefit from bevacizumab treatment, for exam-
ple in gastric cancer [12] and metastatic breast cancer [13]. 
Therefore, it is important to evaluate baseline VEGF-A as a 
covariate. The reason why these important covariates were 
not evaluated in the previous analysis is likely that these 
evidences showing the importance of these covariates all 
appeared after the previous analysis, and therefore, the sig-
nificance of these covariates may not have been fully real-
ized at that time, and/or the data were unavailable at that 
time.
Other limitations of the previous analysis include utili-
zation of FO (first-order) instead of FOCE (first-order con-
ditional estimation) algorithm in NONMEM [14], limited 
number of studies (n = 6), patients (n = 491) and indica-
tions (mainly CRC, NSCLC and breast cancer), etc. There-
fore, an updated analysis is warranted.
The objectives of the current analysis were to develop 
a robust population PK model in adult patients with solid 
tumors and to evaluate the influence of patient variables on 
bevacizumab PK, which can be used to simulate bevaci-
zumab exposure to optimize bevacizumab dosing strategies.
Methods
Patients
Studies in adult cancer patients included in this analysis 
are summarized in Table 1. Patients with at least one PK 
sample were evaluated. Serum bevacizumab concentrations 
were determined at Genentech, Inc., using an enzyme-
linked immunosorbent assay that used recombinant human 
VEGF for capture and a goat antibody to human IgG con-
jugated to horseradish peroxidase for detection. The low-
est limit of quantification (LLOQ) was 78 ng/mL in serum 
[9]. Concentrations below the LLOQ were omitted. The 
clinically relevant covariates tested included those related 
to demographics, biochemical tests, concomitant medi-
cations and pathophysiological factors (Table 2). Val-
ues of covariates that follow lognormal distribution were 
Table 1  Summary of studies
CRC metastatic colorectal cancer, HRPC hormone refractory pros-
tate cancer, N number of patients or samples included in this analysis, 
NSCLC non-small cell lung carcinoma, RCC renal cell carcinoma
a Adjuvant setting
Study Indication Phase N Patients N Samples
Model-building population
AVF0737g [9] Solid tumors I 15 332
AVF0757g [9] NSCLC II 60 1083
AVF0761g [9] Solid tumors I 12 239
AVF0775g HRPC II 15 255
AVF0776g [27] Breast cancer II 74 910
AVF0780g [28] CRC II 65 1077
AVF2107g [29] CRC III 215 607
AVF2119g [30] Breast cancer III 35 124
AVF3077s [31] Colon cancera IV 679 974
BO17704 [32] NSCLC III 138 1064
BO17705 [33, 34] RCC III 102 397
BO17706 [35] Pancreatic cancer III 80 241
BP20689 [36] Solid tumors I 37 712
BO21015 [37] NSCLC II 251 856
BO21990 [38] Glioblastoma III 14 72
Total 1792 8943
External validation population
JO18157 CRC I 18 422
JO19901 [39] Breast cancer II 69 704
JO19907 [40] NSCLC II 59 544
Total 146 1670
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log-transformed. Bevacizumab was given via intravenous 
infusion of 30–90 min in all patients.
Population pharmacokinetic modeling
A population PK model was developed using data from 15 
studies: AVF0737g, AVF0757g, AVF0761g, AVF0775g, 
AVF0776g, AVF0780g, AVF2107g, AVF2119g, AVF3077s, 
BO17704, BO17705, BO17706, BP20689, BO21015 and 
BO21990. Nonlinear mixed-effects modeling was per-
formed with NONMEM (version 7.2; ICON Development 
Solutions, Ellicott City, Maryland, USA) [14] using the 
FOCE method with interaction, Perl-speaks-NONMEM 
(version 3.5.3; Uppsala University, Uppsala, Sweden) [15] 
and R 3.0.3 [16]. Several models with various residual 
error structures and OMEGA matrices were tested to select 
the optimal base model. The base model included a power 
function of body size [e.g., total body weight (BWT)] on 
all PK parameters:
where BWTi = baseline BWT of patient i; Pi = typical PK 
parameters of patients with BWTi; PTV = typical value of 





Table 2  Summary of patient 
characteristics
ALBU baseline albumin (g/L), BSA baseline surface area (m2), BWT baseline body weight (kg), N number 
of patients with available data, SD standard deviation, TPRO baseline total protein (g/L)

















































Gender 1792 Female: 843 (47 %)
Male: 949 (53 %)
146 Female: 103 (70.5 %)
Male: 43 (29.5 %)
Race 1113 Caucasian: 929 (51.8 %)
Asian: 67 (3.7 %)
Black: 49 (2.7 %)
Hispanic: 17 (0.9 %)
Other: 51 (2.8 %)
146 Asian: 146 (100 %) 
Renal function 1753 Normal: 891 (49.7 %)
Mild impairment: 666 (37.2 %)
Moderate impairment: 196 (10.9 %)
146 Normal: 81 (55.5 %)
Mild impairment: 58 (39.7 %)
Moderate impairment: 7 (4.8 %)
Concomitant 
treatment
1792 Single agent: 104 (5.8  %)
Chemotherapy: 1586 (88.5 %)
Interferon alpha: 102 (5.7 %)
146 Single agent: 18 (12.3 %)
Chemotherapy: 128 (87.7 %)
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PK parameters for patients with BWT of 70 kg; θP = expo-
nent for the PK parameter P.
The base model was evaluated using either theoreti-
cal (0.75 for clearances and 1 for volumes of distribution) 
[17] or fitted values of exponents θP. The quality of fit was 
evaluated using a standard model discrimination process 
including statistical criteria [i.e., minimum of objective 
function value (OFV)], adequate estimation of the param-
eters (e.g., relative standard error <50 %) and graphical 
representations of goodness of fit. The final model was 
established in a stepwise manner by forward addition fol-
lowed by backward elimination of parameter–covari-
ate relationships with a significance level of p < 0.01 and 
p < 0.001, respectively (OFV decrease of 6.63 and 10.83 
for one degree of freedom based on Chi-squared distribu-
tion, respectively).
The effect of n covariates at baseline on PK parameters 
was coded using a multiplicative model:
where θi is the typical value of the parameter for patients 
with a set of covariates i, θTV is the typical value of the PK 
parameter for patients having the covariate values equal to 
the median of the covariate for all patients, and Effect1,i 
through Effectn,i are multiplicative factors of the effects for 
covariate 1 through n, for the set of covariates i. The covari-
ate models for both continuous and categorical covariates 
were chosen to avoid prediction of negative parameter 
values.
The multiplicative factor was defined using the power 
function for continuous covariates:
and defined as follows for categorical covariates:
if this categorical covariate is equal to 0, then Effecti = 1
if this categorical covariate is not equal to 0, then 
Effecti = eθeff
where Effecti is the multiplicative factor of the covari-
ate effect for covariate i at baseline, Covi is the covariate 
value, Covreference value is the median of the covariate for all 
patients, and θeff is the exponent of the power function to be 
estimated. eθeff was used for categorical covariates to force 
a positive value.
For patients with missing value for a continuous covariate 
Covi, the multiplicative factor of Covi was calculated as [18]:











where θcov missing is the value of the covariate that was esti-
mated by fitting to the data from all patients with missing 
information. During the forward addition step, θcov missing was 
estimated by fitting to the data for all covariates with missing 
values. During the backward elimination step, θcov missing was 
fixed to the estimates obtained from the forward addition 
step to stabilize the model. All patients with missing value 
had the same estimate of θcov missing.
Model evaluation and sensitivity analysis
The population PK models were evaluated using diag-
nostic plots [19, 20], visual predictive check (VPC) [20, 
21], prediction-corrected VPC (pcVPC) [22], bootstrap-
ping [23] and shrinkage [24] assessments. VPC, pcVPC 
and bootstrapping were all performed using 2000 rep-
licates based on the final model. The relative impact of 
each covariate included in the final model alone on PK 
parameters and exposure was explored. Exposure includ-
ing the trough (Cmin) and peak (Cmax) concentration was 
computed at steady state given bevacizumab of 10 mg/kg 
once every 2 weeks using the final model. The computa-
tion was performed using the extreme covariate values 
(5th and 95th percentiles) and the equations of the final 
model.
External validation
After the final model was built, data from three Japa-
nese studies (JO18157, JO19901 and JO19907, Tables 1 
and 2) became available and were subsequently used 
for external validation. Predicted bevacizumab con-
centrations (CIPRED) for the validation population were 
obtained using post hoc Bayesian forecasting by fix-
ing the parameters in the structural and variance mod-
els to the final estimates. Prediction errors (PEs) as a 
measure of bias were calculated for each concentration 
as PE = (CIPRED − COBS)/COBS, where COBS denotes 
observed concentrations. Root mean squared prediction 







2, where n denotes the number 
of observations. pcVPC approach was used to compare 
the 95 % prediction interval and OBS.
Predicted PK parameters (PIPRED) for each patient were 
calculated based on individual covariate values using the 
equations in the final model without considering observed 
concentrations. Post hoc estimates of PK parameters (PEST) 
were obtained based on observed concentrations and the 
final model. PE was calculated as (PIPRED − PEST)/PEST. 







n denotes the number of patients.




A total of 8943 bevacizumab serum concentrations from 
1792 adult cancer patients in 15 studies were included in 
the model-building dataset, and 1670 concentrations from 
146 adult patients in three Japanese studies were included 
in the external validation dataset. Studies and patient char-
acteristics are summarized in Tables 1 and 2. Less than 5 % 
of the samples were below LLOQ, and all of them were 
pre-dose samples.
Population pharmacokinetic modeling
The optimal base model was a linear two-compartment 
model with theoretical exponents estimated for clearance 
(CL), inter-compartment clearance (Q), central (V1) and 
peripheral (V2) volumes of distribution, full block inter-
individual variability (IIV) on CL, V1 and V2 with com-
bined additive and proportional residual error. Parameter 
estimates of the base model are presented in Supplemen-
tary Table 1. In the base model, the estimates of typical 
bevacizumab CL, V1, Q, V2 and terminal half-life values 
for a 70-kg patient were 9.01 mL/h, 2880 mL, 18.7 mL/h, 
2571 mL and 19.6 days. Thirty-eight covariate relation-
ships were evaluated in the forward addition step. After 
adjusting for total body weight (BWT), CL and V1 were 
still higher in male patients. CL decreased with increasing 
albumin (ALBU) and decreasing baseline alkaline phos-
phatase (BALP). CL was also lower in patients treated with 
interferon alpha (Supplementary Fig. 1). No covariate was 
excluded during the backward elimination step (p < 0.001).
Parameter estimates of the final model are summarized 
in Table 3. Bevacizumab CL and V1 for the patient i were 
described as follows (ALBU = 41.8 and BALP = 76.3 if 
missing):
Model evaluation and sensitivity analysis
Goodness-of-fit plots showed good agreement between 
predicted and observed bevacizumab concentrations with 
no apparent bias in residual (Supplementary Fig. 2). The 
pcVPC result for the final model is presented in Fig. 1. 
Overall, the 2.5th, 50th and 97.5th percentiles of observed 
concentrations were within the predicted 95 % confidence 
interval (CI) of these percentiles, suggesting accurate 
model fitting across a wide range of dosing regimens and 
time courses. Bootstrapping resulted in median parameter 
estimates and 95 % CIs similar to the estimates from the 
original dataset, indicating that the final model provided 
good precision for parameter estimation.
The impact of the variation for a single covariate 

















× (1.14 for males)






× (1.18 for males)
Table 3  Parameter estimates of the final model in adult cancer 
patients
Add. additive, ALBU baseline albumin, BALP alkaline phosphatase, 
CI confidence interval, CL clearance (mL/h), IIV inter-individual vari-
ability, IFNa interferon alpha treatment, Prop. proportional, Q inter-
compartment clearance, V1 central volume of distribution, V2 periph-
eral volume of distribution
a Value of the exponent θeff estimated in the model
b Values calculated as “eθeff,” where θeff is the value of covariate 
effect for male estimated with the model
Parameter Estimate Shrinkage (%) Bootstrap
Median 95 % CI
CL (mL/h) 8.6 8.6 [8.37, 8.82]
V1 (mL) 2678 2678 [2616, 2736]
Q (mL/h) 18.6 18.7 [16.6, 21.3]
V2 (mL) 2423 2417 [2291, 2568]
BWT on CL 
and Qa
0.589 0.586 [0.501, 0.666]
Male on CLb 1.14 1.15 [1.11, 1.19]










IFNa on CLa 0.844 0.843 [0.780, 0.905]
BWT on V1 
and V2a
0.470 0.469 [0.396, 0.541]
Male on V1b 1.18 1.18 [1.13, 1.22]
Prop. error 
(%)
21.8 12.0 21.7 [20.7, 22.9]
Add. error 
(μg/mL)
0.0553 12.0 0.0553 [0.0438, 
0.0678]
IIV CL (%) 29.2 17.7 29 [27.2, 31.0]
IIV V1 (%) 18.3 44.3 18.2 [15.6, 20.9]
IIV V2 (%) 41.4 43.8 41.8 [33.2, 49.3]
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(Fig. 2a, b), CL (Fig. 2c) and V1 (Fig. 2d) and steady-state 
exposure (Fig. 2) is demonstrated by comparing the simu-
lated CL, V1 and exposure of patients with extreme covari-
ate values (5th and 95th percentiles) to a typical patient 
with median covariate value. Among all covariates, BWT 
had the strongest impact on CL (change at extreme BWT 
values: −17.4 to 30.3 %) and V1 (change at extreme BWT 
values: −14.1 to 23.5 %). The impact of other covariates on 
CL (<22 %) and V1 (<18 %) was low. BWT had the strong-
est impact on Cmin (30.3 %) and Cmax (37.6 %). The impact 
of the variation for other covariates on Cmin and Cmax was 
all below 30 %.
External validation
Over 95 % of prediction-corrected observations fell within 
the 95 % prediction interval (PI) (Fig. 3). CL and V1 cal-
culated based on the equations in the final model (PIPRED) 
were similar to those estimated based on observed con-
centrations (PEST) (Fig. 4a, b). Mean PE for bevacizumab 
serum concentrations, CL and V1 were −2.1, 3.1 and 
1.0 %, respectively. No bias in PE was observed over time 
and across predicted values. RMSE for bevacizumab serum 
concentrations, CL and V1 were 0.283, 0.017 and 2.60, 
respectively.
Post hoc Bayesian estimates of CL and V1 in the model-
building population (mostly non-Asian patients) and exter-
nal validation population (Japanese patients only) were 
also similar after normalization by individual covariate val-
ues that were included in the final model (Fig. 4c, d). The 
normalization was done by dividing the post hoc Bayesian 
estimates of CL and V1 by the individual covariate val-
ues in the form that appeared in the equations of the final 
model.
Discussion
This analysis is a comprehensive PK evaluation of bevaci-
zumab in adult cancer patients in Phases I–IV studies as a 
single agent or in combination with chemotherapy for both 
single- and multiple-dose administration with both rich and 
sparse bevacizumab serum concentration data. A robust 
population PK model was built based on a large PK popu-
lation of 1792 patients from 15 studies and then externally 
validated using data from 146 Japanese patients in three 
independent studies. This model consolidated all bevaci-
zumab PK data in one model, can timely support simula-
tions and decision making when needed, can help develop 
consistent pharmacokinetic messages of bevacizumab for 
investigators and health authorities given that multiple PK 
models have been developed for bevacizumab and con-
tained inconsistent messages, and can support future stud-
ies of bevacizumab in other indications. As mentioned in 
the “Introduction,” many important covariates that were 
not evaluated in the previous analysis (e.g., Asian vs. 
Fig. 1  Prediction-corrected visual predictive check for the serum concentration-time profiles of bevacizumab using the final model in adult can-
cer patients. Pred population prediction; figure on the right is the part of figure on the left during the first 2 months after dose
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Fig. 2  Impact of the variation for a single covariate included in the 
final model on steady-state bevacizumab exposure and PK param-
eters in adult cancer patients: a Cmin (minimum concentration); b 
Cmax (maximum concentration); c CL (clearance); d V1 (central vol-
ume of distribution). Red vertical lines represent the “base” defined 
as the exposure or PK parameter estimate of a typical patient, i.e., a 
70-kg female patient with albumin of 39 g/L and baseline alkaline 
phosphatase of 109 U/L without interferon alpha treatment. The 
dark blue shaded curve at the bottom with value at each end shows 
the 5th to 95th percentile range of exposure or PK parameter estimate 
across the entire population. Each light blue shaded bar represents 
the influence of a single covariate on the steady-state exposure after 
repeated bevacizumab dose of 10 mg/kg once every 2 weeks or on the 
PK parameter. The label at left end of the bar represents the covariate 
being evaluated. The upper and lower values for each covariate cap-
ture 90 % of the plausible range in the population. The length of each 
bar describes the potential impact of that particular covariate on beva-
cizumab steady-state exposure or PK parameters, with the percentage 
value in the parentheses at each end representing the percent change 
from the “base.” The most influential covariate is at the bottom of the 
plot for each exposure metric or PK parameter
348 Cancer Chemother Pharmacol (2016) 78:341–351
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Fig. 2  continued
Fig. 3  External validation. 
Most of prediction-corrected 
observations fall between the 
95 % prediction intervals. There 
is no apparent systematic bias in 
prediction
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non-Asian, indications, baseline VEGF-A) were evaluated 
in this analysis.
Typical population PK parameter estimates were similar 
as previously published [9]. The low IIV of 29 and 18.3 % 
observed for CL and V1 was typical for antibody drugs 
[25]. The pcVPC demonstrated adequate fit and predic-
tive performance of the final model (Fig. 1). The median 
prediction (blue band) may appear to be slightly below the 
median observation (blue line) beyond day 112, suggest-
ing a possible tendency of under-prediction. However, this 
tendency is likely irrelevant given (1) the small degree of 
under-prediction, (2) the sparseness of data beyond day 
112, (3) the good predictive performance for 2.5th and 
97.5th percentiles (red) across all time points, as well as 
(4) the complexity and heterogeneity of the data. The exter-
nal validation (Figs. 3, 4) demonstrated good predictive 
performance of the final model with no apparent systemic 
bias and the similarity in bevacizumab PK between Asian 
and non-Asian adult cancer patients. Although there may 
appear to be a tendency of over-prediction of the variability 
(Fig. 3), this tendency is likely irrelevant because the model 
was built based on more heterogeneous data (15 studies 
over a decade across various ethnic groups) while the vali-
dation data were more homogeneous (three studies over a 
few years in Asian patients only).
Factors significantly associated with bevacizumab 
PK were similar as previously published [9]: CL and V1 
increased with BWT and were higher in males, and CL 
decreased with increasing albumin and decreasing BALP. 
It is well known that CL of other IgG antibodies is faster in 
patients with lower serum albumin levels [25], likely due 
to two reasons. First, the level of albumin correlates with 
disease status. Second, the recycling of albumin and IgG 
is both mediated by FcRn (neonatal Fc receptor) [25], and 
therefore, albumin levels may reflect the abundance and 
efficiency of FcRn. The effect of BALP on bevacizumab 
CL is likely because BALP is an indicator of disease bur-
den, such as liver or bone metastases. CL was found to 
be 15.6 % lower in patients treated with interferon alpha. 
However, this effect was within the overall PK variability 
and therefore may be clinically irrelevant.
Similar to the previous analysis [9], tumor burden was 
not included in the final model in this analysis. Among 
solid tumors, tumor burden is usually an indicator of dis-
ease severity and health status. It is usually defined as the 
sum of longest diameters of target lesions under RECIST 
(Response Evaluation Criteria in Solid Tumors) criteria 
for systematic tumors and under other criteria for other 
tumors (e.g., brain tumors). Inclusion of tumor burden in 
bevacizumab PK model may not be crucial. First, tumor 
burden as an indicator of disease burden and health sta-
tus could already be represented by albumin and BALP in 
the model. Second, tumor burden as a source of VEGF-A 
(target of bevacizumab) is irrelevant for bevacizumab PK 
because bevacizumab molar concentration is thousands of 
times higher than that of VEGF-A [10], and there has been 
no evidence of target-mediated drug disposition (TMDD) 
for bevacizumab [10]. Third, in previous analyses, tumor 
Fig. 4  Comparison between (a, 
b) individual CL (a) and V1 (b) 
calculated based on individual 
covariate values using the equa-
tions in the final model without 
considering observed concentra-
tions and post hoc estimates of 
CL and V1 obtained based on 
observed concentrations and 
the final model in the external 
validation population, and 
between (c, d) post hoc Bayes-
ian estimates of CL (c) and V1 
(d) of the model-building popu-
lation and external validation 
population after normalization 
by individual covariate values 
that were included in the final 
model. Gray diamond in the 
boxplots represents the mean. 
CL clearance, Cov covariates 
included in the final model. 
V1 central volume of distribu-
tion. In Fig. 4c, d, data points 
with CL < 3 mL/h (n = 2) or 
V1 < 1500 mL (n = 1) are not 
displayed
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burden alone showed relatively low impact on bevacizumab 
exposure in the sensitivity analysis (similar to Fig. 2, data 
not published). Finally, the final model demonstrated ade-
quate fitting and superior predictive performance without 
incorporating tumor burden.
On the other hand, three factors made it impossible to 
test baseline tumor burden as a covariate in this analysis. 
First, tumor response criteria were inconsistent across 
these 15 studies that were conducted across a time span of 
over a decade. Several different versions of RECIST and 
other criteria (e.g., Macdonald criteria for glioblastoma in 
BO21990) were used. Second, the methods used to meas-
ure tumor burden were inconsistent across studies, such as 
CT (computerized tomography) scans and MRI (magnetic 
resonance imaging). Finally, unit of length (mm) and area 
(mm2) both exist in tumor burden data, which cannot be 
converted to each other. In fact, inclusion of tumor bur-
den in the model would greatly reduce the applicability 
of the model due to the continuous advancement in tumor 
response criteria and measurement methods, and due to 
different tumor response criteria and measurement meth-
ods across cancer types, for example RECIST version 1.0 
versus version 1.1, RECIST criteria versus Macdonald 
criteria or RANO (Response Assessment in Neuro-Oncol-
ogy) criteria, CT scans versus MRI.
In conclusion, a robust population PK model for beva-
cizumab in adult cancer patients was built and externally 
validated, which may be used to simulate concentration-
time profile in adult cancer patients in future studies [11, 
26]. Baseline body weight, albumin, alkaline phosphatase 
and gender were the covariates with the greatest influence 
on bevacizumab CL and V1, supporting body weight-based 
dosing of bevacizumab. No difference in bevacizumab PK 
was observed between Asian and non-Asian patients. Given 
the similarity in PK among many monoclonal antibod-
ies, this may inform PK studies in different ethnic groups 
(e.g., Asian vs. non-Asian) for other therapeutic antibod-
ies without TMDD and significant race-dependent target 
expression.
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